Aclarion announces commercial agreement with Weill Cornell Medicine

Aclarion (ACON) announced it has established a commercial agreement with Weill Cornell Medicine. The agreement brings Nociscan to Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center and the multidisciplinary spine team. The trial is entitled “A Prospective Review of Bone Marrow Aspirate Stem Cell Concentrate for Osteoarthritis and Degenerative Disc Disease,” conducted under IRB Protocol No. 22-06024915. The purpose of this initial study is to investigate whether the dose and quantity of bone marrow aspirate stem cell concentrate used for the treatment of osteoarthritis and/or Degenerative Disc Disease in the spine has an effect on patient-reported functional outcomes and pain. A subset of spine patients will also be eligible for Nociscan.